Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ArriVent BioPharma (AVBP) Return on Capital Employed (2024 - 2026)

ArriVent BioPharma has reported Return on Capital Employed over the past 3 years, most recently at 49.61% for Q1 2026.

  • Quarterly results put Return on Capital Employed at 49.61% for Q1 2026, up 1084.0% from a year ago — trailing twelve months through Mar 2026 was 49.61% (up 1084.0% YoY), and the annual figure for FY2025 was 63.84%, down 1709.0%.
  • Return on Capital Employed reached 49.61% in Q1 2026 per AVBP's latest filing, up from 58.42% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 28.15% in Q2 2024 and bottomed at 66.56% in Q2 2025.
  • Median Return on Capital Employed over the past 3 years was 49.61% (2026), compared with a mean of 47.27%.
  • The largest annual shift saw Return on Capital Employed crashed -3841bps in 2025 before it skyrocketed 1084bps in 2026.
  • Over 3 years, Return on Capital Employed stood at 35.38% in 2024, then plummeted by -65bps to 58.42% in 2025, then increased by 15bps to 49.61% in 2026.
  • Business Quant data shows Return on Capital Employed for AVBP at 49.61% in Q1 2026, 58.42% in Q4 2025, and 58.75% in Q3 2025.